233 related articles for article (PubMed ID: 30677523)
1. D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation.
Schoubben A; Vivani R; Paolantoni M; Perinelli DR; Gioiello A; Macchiarulo A; Ricci M
Eur J Pharm Sci; 2019 Mar; 130():54-64. PubMed ID: 30677523
[TBL] [Abstract][Full Text] [Related]
2. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
4. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
5. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
Rattanupatam T; Srichana T
Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
[TBL] [Abstract][Full Text] [Related]
6. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
Kaewjan K; Srichana T
Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
[TBL] [Abstract][Full Text] [Related]
8. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
9. Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying.
Leng D; Thanki K; Foged C; Yang M
Pharm Res; 2018 Nov; 35(12):247. PubMed ID: 30386927
[TBL] [Abstract][Full Text] [Related]
10. Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.
Rashid MA; Muneer S; Wang T; Alhamhoom Y; Rintoul L; Izake EL; Islam N
PLoS One; 2021; 16(4):e0249683. PubMed ID: 33848310
[TBL] [Abstract][Full Text] [Related]
11. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying.
Lu W; Rades T; Rantanen J; Yang M
Int J Pharm; 2019 Jun; 565():1-8. PubMed ID: 30999050
[TBL] [Abstract][Full Text] [Related]
12. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
13. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
Momin MAM; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Jul; 45(7):1205-1213. PubMed ID: 30990097
[TBL] [Abstract][Full Text] [Related]
14. Optimization and characterization of dry powder of fanhuncaoin for inhalation based on selection of excipients.
Yang XB; Wang XB; Pan WS; Xi RG; Wang YN; Liu D; Shi Y; Jiang S
Chem Pharm Bull (Tokyo); 2011; 59(8):929-37. PubMed ID: 21804235
[TBL] [Abstract][Full Text] [Related]
15. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
[TBL] [Abstract][Full Text] [Related]
16. Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance of salbutamol sulfate from DPI formulations.
Molina C; Kaialy W; Chen Q; Commandeur D; Nokhodchi A
Drug Deliv Transl Res; 2018 Dec; 8(6):1769-1780. PubMed ID: 29260462
[TBL] [Abstract][Full Text] [Related]
17. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
18. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
19. Co-spray dried carbohydrate microparticles: crystallisation delay/inhibition and improved aerosolization characteristics through the incorporation of hydroxypropyl-β-cyclodextrin with amorphous raffinose or trehalose.
Amaro MI; Tajber L; Corrigan OI; Healy AM
Pharm Res; 2015 Jan; 32(1):180-95. PubMed ID: 25074469
[TBL] [Abstract][Full Text] [Related]
20. Leucine as an excipient in spray dried powder for inhalation.
Alhajj N; O'Reilly NJ; Cathcart H
Drug Discov Today; 2021 Oct; 26(10):2384-2396. PubMed ID: 33872799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
